NCT07151924|Active Not Recruiting
Eating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy
CALI-BF
Loading search results
CALI-BF
Sponsor study identifier
Secondary identifiers
OTHER · 2025-A01127-42
observational
100
1 country
1
Study Start
September 4, 2025
Actual (reported)Primary Completion
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The prevalence of eating disorders is particularly high among people with type 1 diabetes (T1D). These abnormalities, such as "diabulimia," are frequently responsible for poor insulin therapy management and, consequently, chronic glycemic imbalance, exposing them to an increased risk of complications. Their detection and management unfortunately remain insufficient in current practice. However, to date, no study has addressed the question of the prevalence and impact of eating disorders in this context. Our research hypotheses are therefore as follows:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 18, 2025
Actual (reported)September 3, 2025
Actual (reported)September 4, 2025
Actual (reported)February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Prevalence of eating disorders
The primary outcome measure for establishing the prevalence of eating disorders is a composite outcome measure based on determining the existence of eating disorders \[ED\] by analyzing responses to the mSCOFF questionnaire (score ≥ 2) and/or problematic eating behaviors \[PEB\] by analyzing responses to the QACD questionnaire (score ≥ 20).
6 months after the inclusion
Prevalence of eating disorders (EDs)
6 months after the inclusion
Clinical characteristics at inclusion
6 months after the inclusion
Clinical characteristics at inclusion
6 months after the inclusion
Clinical characteristics at inclusion
6 months after the inclusion
Clinical characteristics at inclusion
6 months after the inclusion
Patients with type 1 diabete with closed-loop therapy
Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.
Collection of HbA1c level and continuous glucose monitoring data
patients with type 1 diabetes for whom closed-loop insulin therapy has been recommended
Diabetology, Metabolic Diseases and Nutrition Department Rangueil Hospital, Toulouse University Hospital 1 avenue du Pr Jean Poulhès
Toulouse, 31059, France
First Submitted
July 18, 2025
First Posted
September 3, 2025
Study Start
September 4, 2025
Actual (reported)Primary Completion
February 28, 2027
EstimatedAutomated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 28, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 24, 2025
Record last verified: 2025-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: